Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Imperial Innovations - Commercialisation deals signed

14 January 2008

Imperial Innovations Group plc

(“Imperial Innovations”)

Commercialisation deals signed

Imperial Innovations Group plc (AIM: IVO), today announces that it has signed commercialisation contracts with a number of healthcare organisations.

· Two Licences relating to research tools have been concluded with Novartis Institutes for BioMedical Research, Inc. and Alcon, Inc. a global company specialised in eye care products.

· Patents on Eotaxin and corresponding antibodies for research applications have been licensed to Invitrogen Corporation, a leading international supplier of reagents for the life sciences and biomedicine. Eotaxin is a protein associated with the migration of white blood cells to inflammatory tissues in disease states, and is currently the subject of intensive research.

· An option agreement has been signed with Emiliem, Inc. a biopharmaceutical company developing molecular targeted cancer therapies, for a family of patents relating to an inhibitor of Protein Kinase B (PKB or Akt), which is a validated cancer target.

Susan Searle, CEO Imperial Innovations said, “The Biosciences team at Imperial Innovations have been working hard to source and market technologies, find suitable commercialisation partners and conclude these deals. These four deals added to our portfolio demonstrate the continuing breadth of opportunities coming through our technology pipeline.”


For more information contact:

Imperial Innovations

Susan Searle, Chief Executive Officer
+44 (0)20 7594 6591

Lucy Ahfong, Marketing Communications Executive
+44 (0)20 7594 6644


Patrick d’Ancona / Eleanor Williamson
+44 (0)20 7153 1539

JP Morgan Cazenove (NOMAD to Imperial Innovations)

Steve Baldwin
+44(0)20 7588 2828

Notes to Editors

About Imperial Innovations
Imperial Innovations is one of the UK's leading technology transfer and commercialisation companies. The company was founded in 1986 and its ordinary shares admitted to trading on the AIM Market of London Stock Exchange plc in July 2006, raising £25 million at an offer price of 365p and £1 million by means of a public offer. In November 2007, the company raised a further £30 million by means of a placing of new ordinary shares with investors.

The company’s integrated approach encompasses the identification of ideas, protection of intellectual property, development and licensing of technology and formation, incubation and investment in technology businesses. A wide range of technologies are commercialised within the areas of healthcare, energy, environment and emerging technology trends.

Based at Imperial College London, the company has established equity holdings in 74 technology businesses and is managing 133 commercial agreements as of 31 July 2007. Imperial Innovations also commercialises technologies originating from outside Imperial College through incubation contracts with the Carbon Trust and WRAP and has commercialisation contracts with a number of multinational corporations including BAE Systems.

Publisher Contact Information:

Imperial College Innovations Limited
+44 (0)20 7594 6591

Company profile of Touchstone Innovations (formerly Imperial Innovations)
Past press releases of Touchstone Innovations (formerly Imperial Innovations).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices
Sep 12€9.0MSoftware development

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.